9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)

Inventors

Tzanis, Evangelos L. • McGovern, Paul • Manley, Amy L. • Garrity-Ryan, Lynne • Tanaka, S. Ken

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10835542-B2

Patent

Publication Date

2020-11-17

Expiration Date


Abstract

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

Core Innovation

The disclosure describes methods for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline, also identified as omadacycline, or a salt thereof. The claimed methods encompass intravenous-to-oral regimens as well as oral-only regimens comprising an initial oral phase followed by subsequent oral dosing. The background section is omitted from the supplied content, so the underlying problem being solved is not explicitly described in patent.

The claims cover CABP treatment utilizing an initial intravenous phase optionally followed by additional intravenous treatment and oral step-down dosing, or oral regimens with initial doses followed by subsequent doses. Reported clinical and study data compare omadacycline with moxifloxacin for early CABP response, post-therapy clinical success, and adverse event profiles. The specific dose amounts and administration intervals are [procedural detail omitted for safety].

Claims Coverage

The claim coverage includes four inventive features across independent claims covering treatment regimens for Community-Acquired Bacterial Pneumonia using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.

Intravenous treatment followed by optional intravenous and oral treatment

The claim covers treating CABP with the specified compound or a salt thereof through an initial intravenous phase, optionally followed by further intravenous treatment and oral treatment. The specific dose amounts and administration intervals are [procedural detail omitted for safety].

Intravenous treatment followed by oral treatment

The claim covers treating CABP with the specified compound or a salt thereof through an initial intravenous phase, optionally followed by additional intravenous treatment and then oral treatment. The specific dose amounts and administration intervals are [procedural detail omitted for safety].

Oral treatment with an initial and subsequent phase

The claim covers treating CABP with the specified compound or a salt thereof using an initial sequence or phase of oral treatment, optionally followed by further oral treatment. The specific dose amounts and administration intervals are [procedural detail omitted for safety].

Oral treatment with initial doses followed by subsequent doses

The claim covers treating CABP with the specified compound or a salt thereof using initial once-daily oral treatment followed by further oral treatment. The specific dose amounts and administration intervals are [procedural detail omitted for safety].

The four independent claims cover CABP treatment using the specified compound or a salt thereof via intravenous-to-oral or oral-only approaches, with dependent claims reciting refinements relating to the treatment population, salt forms, treatment outcomes, and administration conditions.

Stated Advantages

Clinical data report omadacycline as non-inferior to moxifloxacin for early CABP response and post-therapy clinical success in reported populations, including the PORT Risk Class III/IV subgroup, with a dependent claim specifying a clinical success rate within a stated non-inferiority margin.

Safety-population results report fewer subjects with treatment-emergent adverse events and drug-related adverse events for omadacycline than for moxifloxacin.

The Phase 1 study summary reports that studied oral doses were generally tolerated and identifies an oral dose as a potential loading dose before subsequent oral treatment or as an oral treatment dose.

A dependent claim specifies improvement in at least two CABP symptoms from baseline during the stated assessment period.

A dependent claim states that treatment does not increase the subject's risk of C. difficile infection or substantially disrupt the gut microbiome.

Documented Applications

Treatment of Community-Acquired Bacterial Pneumonia (CABP) in a subject in need of treatment, including CABP associated with bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.